Risk factors for incidental prostate cancerwho should not undergo vaporization of the prostate for benign prostate hyperplasia?

Prostate

Volumn 71, Issue 12, 2011, Pages 1325-1331

  Voigt, Susan ^a,b   Hüttig, Friederike ^a   Koch, Rainer ^a   Propping, Stefan ^a   Propping, Catharina ^a   Grimm, Marc Oliver ^b   Wirth, Manfred ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

clinically relevant prostate cancer; digital rectal examination; prostate cancer risk calculation; PSA; vaporization of the prostate

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; BODY MASS; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; GLEASON SCORE; HUMAN; HUMAN TISSUE; INCIDENTALOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; ORGAN WEIGHT; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; TRANSURETHRAL ELECTROVAPORIZATION; TRANSURETHRAL RESECTION;

ADULT; AGED; AGED, 80 AND OVER; BODY MASS INDEX; COUNSELING; DIAGNOSTIC ERRORS; HUMANS; INCIDENTAL FINDINGS; LASER THERAPY; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; ORGAN SIZE; PREDICTIVE VALUE OF TESTS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; TRANSURETHRAL RESECTION OF PROSTATE; VOLATILIZATION;

EID: 79960738827     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21349     Document Type: Article

References (15)

1. Mai KT, Isotalo PA, Green J, Perkins DG, Morash C, Collins JP,. Incidental prostatic adenocarcinomas putative premalignant lesions in TURP specimens collected before and after the introduction of prostate-specific antigen screening. Arch Pathol Lab Med 2000; 124: 1454-1456.
2. Martino P, Palazzo S, Battaglia M, Lucarelli G, Selvaggi FP,. Incidental prostatic cancer: Repeat TURP or biopsy ? Urol Int 2004; 73: 193-197. (Pubitemid 39482696)
3. AndrÃn O, Fall K, Franzén L, Andersson SO, Johansson JE, Rubin MA,. How well does the Gleason score predict prostate cancer death? A 20-year follow-up of a population based cohort in Sweden. J Urol 2006; 175: 1337-1340.
4. AndrÃn O, Garmo H, Mucci L, Anderson S-O, Johansson J-E, Fall K,. Incidence and mortality of incidental prostate cancer: A Swedish register-based study. Br J Cancer 2009; 100: 170-173.
5. Robinson D, Aus G, Bak J, Gorecki T, Herder A, Rosell J, Varenhorst E,. Long-term follow-up of conservatively managed incidental carcinoma of the prostate: A multivariate analysis of prognostic factors. Scand J Urol Nephrol 2007; 41: 103-109. (Pubitemid 46598091)
6. Galejs LE, Hollander JB,. Incidental carcinoma of the prostate in the PSA era. Prostate J 1999; 1: 27-31.
7. Albertsen PC, Hanley JA, Gleason DF, Barry MJ,. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998; 280: 975-980. (Pubitemid 28445095)
8. Cuzick J, Fisher G, Kattan MW, Berney D, Oliver T, Foster CS, Moller H, Reuter V, Fearn P, Eastham J, Scardino P,. The Transatlantic Prostate Group. Long-term outcome among men with conservatively treated localised prostate cancer. Br J Cancer 2006; 95: 1186-1194. (Pubitemid 44658482)
9. DeLong R, DeLong D, Clarke-Pearson D,. Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics 1988; 44: 837-845.
10. Tombal B, De Visccher L, Cosyny JP, Lorge F, Opsomer R, Wese FX, Van Cangh PJ,. Assessing the risk of unsuspected prostate cancer in patients with benign prostatic hypertrophy: A 13-year retrospective study of the incidence and nature history of T1a-T1b prostate cancers. Br J Urol Int 1999; 84: 1015-1020.
11. Cheng L, Bergstralh EJ, Scherer BG, Neumann RM, Blute ML, Zincke H, Bostwick DG,. Prodictors of cancer progression in T1a prostate adenocarcinoma. Cancer 1999; 85: 1300-1304. (Pubitemid 29125083)
12. Eastham JA, Kattan MW, Fearn P, Fisher G, Berney DM, Oliver T, Foster CS, Moller H, Reuter V, Cuzick J, Scardino P,. The Transatlantic Prostate Group. Local progression among men with conservatively treated localized prostate cancer: Results from the transatlantic prostate group. Eur Urol 2008; 53: 347-354.
13. Descazeaud A, Peyromaure M, Salin A, Amsellem-Ouazana D, Flam T, Viellefond A, Debré B, Zerbib M,. Predictive factors for progression in patients with clinical stage T1a prostate cancer in the PSA era. Eur Urol 2007; 53: 355-362.
14. Bostwick DG,. The pathology of incidental carcinoma. Cancer Surv 1995; 23: 7-18.
15. Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J,. The prostate specific antigen era in the United States is over for prostate cancer: What happened in the last 20 years ? J Urol 2004; 172: 1297-1301. (Pubitemid 39249701)